Current Status of Antiviral Treatments in Inpatients Chronically Infected with Hepatitis B Virus
Objective To investigate the current status of antiviral therapy in inpatients chronically infected with hepatitis B virus, and provide evidence for reasonable guidance and optimization of antiviral therapy. Methods According to medical records, to collect the data of antiviral therapy of the inpatients with chronic hepatitis B virus infection in Qingdao Hospital for Infectious Diseases hospitalizied from January to June, 2013, and to analyze the rates of antiviral therapy and the relationships with the characteristics of patients. Results 447 inpatients with chronic hepatitis B virus infection were enrolled, among which 422 cases met the indications for antiviral therapy. The overall rate of antiviral therapy was 84.1%(355 cases). In all the treatment regiments, the proportion of entecavir was the highest(43.4%). The rates of current antiviral therapy in previously untreated patients and treated patients were 79.6 %and 93.0%(P<0.05), respectively. The proportions of monotherapy with adefovir dipivoxil or lamivudine were higher, and combination therapies(nucleos[t]ide analogue plus interferon or combination of nucleos[t]ide analogue) were lower in previously untreated patients than in treated patients(P<0.05). There were no significant difference of antiviral therapy rates between sex and family history or among the durations of disease, age and diagnosis of patients(P>0.05). Conclusion The antiviral therapy of inpatients with chronic hepatitis B virus infection is gradually standardized, but the overall rate of antiviral therapy needs to be further improved.
Antiviral therapyHepatitis BChronicHepatitis B virusInpatients
NETL
NSTL
万方数据
维普
